Publications by authors named "Gary Patou"

Claim this Profile
D
Durable biochemical response and safety with oral octreotide capsules in acromegaly.
Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J Manning, Gary Patou

Eur J Endocrinol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut, Gary Patou

Lancet Diabetes Endocrinol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Murray B Gordon, Marek Bolanowski, Gary Patou

J Clin Endocrinol Metab· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Ulrich Jäger, Shirley D'Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Gary Patou

Blood· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of liposome bupivacaine following various routes of administration in animals.
Girish P Joshi, Gary Patou, Vladimir Kharitonov

J Pain Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia.
Sergio D Bergese, Sonia Ramamoorthy, Gary Patou, Kenneth Bramlett, Stephen R Gorfine

J Pain Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to onset of analgesia following local infiltration of liposome bupivacaine in healthy volunteers: a randomized, single-blind, sequential cohort, crossover study.
Glen Apseloff, Erol Onel, Gary Patou

Int J Clin Pharmacol Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting.
Joseph Dasta, Sonia Ramamoorthy, Gary Patou, Raymond Sinatra

Curr Med Res Opin· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating therapeutic benefit in postsurgical analgesia requires global assessment: an example from liposome bupivacaine in hemorrhoidectomy.
William K Schmidt, Gary Patou, Girish P Joshi

Hosp Pract (1995)· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial.
Stephen R Gorfine, Erol Onel, Gary Patou, Zoran V Krivokapic

Dis Colon Rectum· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vogue with venture.
Gary Patou

Nat Biotechnol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor.
Sandhya Ramanathan-Girish, Juliet McColm, John M Clements, Phil Taupin, Sue Barrowcliffe, Gary Patou

Antimicrob Agents Chemother· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis